Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097256218> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2097256218 abstract "The development of effective, novel, targeted cancer therapies with minimal side effects has long been a goal in cancer research. A key group of targets identified for drug development consists of the receptor tyrosine kinases, which have pivotal roles in the growth factor signaling that is subverted in carcinogenesis and in the host processes, such as angiogenesis, involved in tumor progression.A literature review of the role of receptor tyrosine kinases in human malignancies is followed by a discussion of the potential use of inhibitors of receptor tyrosine kinases as anticancer therapy, focusing on the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839, AstraZeneca, Macclesfield, United Kingdom).Several small molecule inhibitors that are specific to individual receptor tyrosine kinases have been developed and a number of these potential anticancer agents are progressing through clinical trials. Various surrogate end points are being assessed to demonstrate the activity of these inhibitors against their targets. Results from studies of gefitinib alone and with the antiandrogen bicalutamide in both hormone dependent and independent prostate tumor xenografts suggested that gefitinib may have potential as monotherapy and combination therapy in the treatment of both forms of the disease. Gefitinib is currently undergoing further preclinical and clinical evaluation for the treatment of prostate cancer.A number of tyrosine kinase inhibitors, including gefitinib, are progressing through clinical development and are beginning to provide new treatment options for a range of malignancies." @default.
- W2097256218 created "2016-06-24" @default.
- W2097256218 creator A5078201837 @default.
- W2097256218 date "2003-12-01" @default.
- W2097256218 modified "2023-09-23" @default.
- W2097256218 title "Growth Factor Receptor Tyrosine Kinase Inhibitors; Clinical Development and Potential for Prostate Cancer Therapy" @default.
- W2097256218 cites W1639582946 @default.
- W2097256218 cites W1970955548 @default.
- W2097256218 cites W1988506250 @default.
- W2097256218 cites W1996160829 @default.
- W2097256218 cites W2005274511 @default.
- W2097256218 cites W2015293591 @default.
- W2097256218 cites W2037397654 @default.
- W2097256218 cites W2057409901 @default.
- W2097256218 cites W2058413420 @default.
- W2097256218 cites W2062366098 @default.
- W2097256218 cites W2093281866 @default.
- W2097256218 cites W2104431314 @default.
- W2097256218 cites W2104812730 @default.
- W2097256218 cites W2114291028 @default.
- W2097256218 cites W2126314379 @default.
- W2097256218 cites W2142661339 @default.
- W2097256218 cites W2148505656 @default.
- W2097256218 cites W2153534791 @default.
- W2097256218 cites W2167368130 @default.
- W2097256218 doi "https://doi.org/10.1097/01.ju.0000095022.80033.d3" @default.
- W2097256218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14610415" @default.
- W2097256218 hasPublicationYear "2003" @default.
- W2097256218 type Work @default.
- W2097256218 sameAs 2097256218 @default.
- W2097256218 citedByCount "21" @default.
- W2097256218 countsByYear W20972562182012 @default.
- W2097256218 countsByYear W20972562182020 @default.
- W2097256218 crossrefType "journal-article" @default.
- W2097256218 hasAuthorship W2097256218A5078201837 @default.
- W2097256218 hasConcept C101544691 @default.
- W2097256218 hasConcept C121608353 @default.
- W2097256218 hasConcept C126322002 @default.
- W2097256218 hasConcept C143998085 @default.
- W2097256218 hasConcept C170493617 @default.
- W2097256218 hasConcept C180361614 @default.
- W2097256218 hasConcept C26375932 @default.
- W2097256218 hasConcept C2775960820 @default.
- W2097256218 hasConcept C2778311097 @default.
- W2097256218 hasConcept C2778820342 @default.
- W2097256218 hasConcept C2779438470 @default.
- W2097256218 hasConcept C2780192828 @default.
- W2097256218 hasConcept C2780580887 @default.
- W2097256218 hasConcept C42362537 @default.
- W2097256218 hasConcept C502942594 @default.
- W2097256218 hasConcept C71924100 @default.
- W2097256218 hasConcept C98274493 @default.
- W2097256218 hasConceptScore W2097256218C101544691 @default.
- W2097256218 hasConceptScore W2097256218C121608353 @default.
- W2097256218 hasConceptScore W2097256218C126322002 @default.
- W2097256218 hasConceptScore W2097256218C143998085 @default.
- W2097256218 hasConceptScore W2097256218C170493617 @default.
- W2097256218 hasConceptScore W2097256218C180361614 @default.
- W2097256218 hasConceptScore W2097256218C26375932 @default.
- W2097256218 hasConceptScore W2097256218C2775960820 @default.
- W2097256218 hasConceptScore W2097256218C2778311097 @default.
- W2097256218 hasConceptScore W2097256218C2778820342 @default.
- W2097256218 hasConceptScore W2097256218C2779438470 @default.
- W2097256218 hasConceptScore W2097256218C2780192828 @default.
- W2097256218 hasConceptScore W2097256218C2780580887 @default.
- W2097256218 hasConceptScore W2097256218C42362537 @default.
- W2097256218 hasConceptScore W2097256218C502942594 @default.
- W2097256218 hasConceptScore W2097256218C71924100 @default.
- W2097256218 hasConceptScore W2097256218C98274493 @default.
- W2097256218 hasIssue "6S" @default.
- W2097256218 hasLocation W20972562181 @default.
- W2097256218 hasLocation W20972562182 @default.
- W2097256218 hasOpenAccess W2097256218 @default.
- W2097256218 hasPrimaryLocation W20972562181 @default.
- W2097256218 hasRelatedWork W1514134885 @default.
- W2097256218 hasRelatedWork W1837617056 @default.
- W2097256218 hasRelatedWork W2012871610 @default.
- W2097256218 hasRelatedWork W2055903396 @default.
- W2097256218 hasRelatedWork W2184456200 @default.
- W2097256218 hasRelatedWork W2367971684 @default.
- W2097256218 hasRelatedWork W2611589808 @default.
- W2097256218 hasRelatedWork W2624131070 @default.
- W2097256218 hasRelatedWork W3032810487 @default.
- W2097256218 hasRelatedWork W3087282761 @default.
- W2097256218 hasVolume "170" @default.
- W2097256218 isParatext "false" @default.
- W2097256218 isRetracted "false" @default.
- W2097256218 magId "2097256218" @default.
- W2097256218 workType "article" @default.